


## Rauwolscine hydrochloride

<b>Cat. No.:</b>	HY-12710A
<b>CAS No.:</b>	6211-32-1
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>27</sub> ClN <sub>2</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	390.9
<b>Target:</b>	Adrenergic Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 12.5 mg/mL (31.98 mM; ultrasonic and warming and heat to 80°C)  
H<sub>2</sub>O : 5 mg/mL (12.79 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.5582 mL	12.7910 mL	25.5820 mL
	5 mM	0.5116 mL	2.5582 mL	5.1164 mL	
	10 mM	0.2558 mL	1.2791 mL	2.5582 mL	

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Rauwolscine hydrochloride is a potent and specific  $\alpha_2$  adrenergic receptor antagonist with a K<sub>i</sub> of 12 nM.

#### IC<sub>50</sub> & Target

K<sub>i</sub>: 12 nM ( $\alpha_2$  adrenergic receptor)<sup>[1]</sup>

#### In Vitro

[<sup>3</sup>H]Rauwolscine binding to  $\alpha_2$  adrenergic receptor is reversible, stereospecific, and saturable. [<sup>3</sup>H]Rauwolscine specifically labels both the high and low affinity states of the  $\alpha_2$  adrenergic receptor in brain membranes<sup>[1]</sup>. [<sup>3</sup>H]Rauwolscine also behaves as a 5-HT<sub>1A</sub> receptor agonist and this conclusion is compatible with earlier functional studies, indicating that rauwolscine (as well as yohimbine) has agonistic properties at the level of 5-HT autoreceptors<sup>[2]</sup>. When using [<sup>3</sup>H]5-HT as a radioligand, rauwolscine is determined to have relatively high affinity for the human receptor (K<sub>i</sub> human=14.3 nM, K<sub>i</sub> rat=35.8 nM)<sup>[3]</sup>. Saturation studies shows that the affinity of [<sup>3</sup>H]Rauwolscine is similar in mouse, rat, rabbit, dog (2.33-3.03 nM) except man where it is significantly higher (0.98 nM)<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

### Kinase Assay <sup>[1]</sup>

Fresh bovine frontal cortex is incubated in triplicate with [<sup>3</sup>H]Rauwolscine (82 Ci/mM, diluted). Incubation is terminated by filtration under reduced pressure over filters, which are then rinsed with ice cold Tris-HCl buffer, dried overnight and added to disposable glass minivials containing 3.0 mL of a 95% Econofluor/5% Protosol solution. Samples are counted by liquid scintillation spectrometry with an efficiency of 32%. (-) [<sup>3</sup>H]Epinephrine binding to bovine cortex membranes is conducted at 25°C<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Perry BD, et al. [<sup>3</sup>H]rauwolscine (alpha-yohimbine): a specific antagonist radioligand for brain alpha 2-adrenergic receptors. *Eur J Pharmacol.* 1981 Dec 17;76(4):461-4.
- [2]. De Vos H, et al. [<sup>3</sup>H]rauwolscine behaves as an agonist for the 5-HT<sub>1A</sub> receptors in human frontal cortex membranes. *Eur J Pharmacol.* 1991 May 25;207(1):1-8.
- [3]. Wainscott DB, et al. [<sup>3</sup>H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine<sub>2b</sub> (5-HT<sub>2B</sub>) receptor. *Naunyn Schmiedebergs Arch Pharmacol.* 1998 Jan;357(1):17-24.
- [4]. Neylon CB, et al. [<sup>3</sup>H]-rauwolscine binding to alpha 2-adrenoceptors in the mammalian kidney: apparent receptor heterogeneity between species. *Br J Pharmacol.* 1985 Jun;85(2):349-59.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA